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Abstract
Background: Chronic pain has become a major health problem across the world, especially in older adults.
Unfortunately, the effectiveness of medical interventions is modest. Some have argued that assessment strategies should
be improved if the impact of medical interventions is to be improved. Ecological momentary assessment using
smartphones is now considered the gold standard in monitoring in health settings, including chronic pain. However, to
the best of our knowledge, there is no randomized controlled trial to show that telemonitoring using a smartphone app
can indeed improve the effectiveness of medical treatments in adults with chronic pain. The goal of this study will be to
explore the effects of using a smartphone app for telemonitoring adults with chronic pain.
Methods: The study will be a randomized controlled trial with three groups: treatment as usual (TAU), TAU+app,
and TAU+app+alarms. All groups will receive the adequate treatment for their pain, which will be prescribed the
first day of study according to clinical guidelines. Assessment in the TAU group will be the usual at the Pain Clinic, that
is, a paper-and-pencil evaluation at the onset of treatment (beginning of study) and at follow up (end of study, 30 days
later). The other two groups (TAU+app and TAU+app+alarms) will be assessed daily using Pain Monitor, a smartphone
app developed by our multidisciplinary team. Telemonitoring will only be made in the TAU+app+alarms group.
For this group, physicians at the Pain Clinic may decide to adjust pain treatment in response to alarms. Telemonitoring is
not the usual practice at the Pain Clinic and will not occur in the other two groups (TAU and TAU+app), so no changes
in treatment are expected in these groups after the first appointment. The total sample size will be 150, with 50 patients
in each group. The assessment protocol will be the same in all groups and will include pain intensity and side effects of
the medication (primary outcomes), together with several pain-related variables like pain interference, activity level, use
of rescue medication, pain catastrophizing, and pain acceptance, among others.
Discussion: We believe that the present trial has important clinical implications. We think that telemonitoring
using ecological momentary assessment is crucial to improve current interventions for pain. The armamentarium of
available treatments for pain is large, so physicians can turn to different treatments or dosages in the presence of an
undesired event. The use of the app for telemonitoring can allow for this rapid detection of unwanted events,
thus improving patient safety (i.e., withdrawal of treatment causing side effects) and augmenting treatment effectiveness
(i.e., changing an ineffective treatment or dosage). In a time when smartphones are a mainstream technology, we should
take advantage of them in the promotion of health care.
Trial registration: ClinicalTrials.gov, NCT03247725. Registered on 25 July 2017.
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Background
Pain is “a distressing experience associated with actual
or potential tissue damage with sensory, emotional,
cognitive and emotional components” [1]. Pain is some-
times short in duration and disappears as tissues heal.
When this happens pain is considered to be acute.
Unfortunately, pain can also persist over long periods of
time and become chronic. A cutoff of between 3 and 6
months is, in the absence of other criteria (i.e., normal
healing period of an injury), the one proposed to
differentiate acute from chronic pain [2].
Chronic pain has become a major public health problem
due to its high prevalence. This disease is estimated to
affect 20–30% of the adult population across the world
[3–6]. Projections of future prevalence of chronic pain
are not more encouraging. With the rise of life ex-
pectancy, the age distribution of the population is
changing towards the elderly [7]. This is likely to have
important implications for chronic pain as its preva-
lence increases dramatically with age. For example, a
study conducted in Spain showed that the percentage
of individuals with chronic pain increases to 73.5% in
people over 65 years old [8].
Medical interventions are the first-line interventions
recommended in recent guidelines for chronic pain
[9–11]. Unfortunately, support for their effectiveness
is only modest [12]. In fact, the most potent drugs
(i.e., opioids) only seem to reduce pain by 30–40% in
less than half of the patients [13] and a number of
patients experience significant side effects [14]. Likewise,
surgery (i.e., spinal cord stimulation and spinal fusion)
only appears to provide partial reduction in pain intensity
in a subset of patients, and complications after surgery
are frequent [15, 16].
Some have argued that the limited efficacy of medical
treatment for pain might be partly due to deficits in
assessment methodology [12, 17]. For instance, existing
randomized controlled trials (RCTs) in chronic pain tend
to include a reduced number of measurement points.
This is a problem because pain-related variables, such as
pain intensity and fatigue, can vary across and within
days [18]. Also, when continuous assessment has been
included, studies have mostly relied on paper diaries or
recalled information, which might be problematic
because of fake data entry, disagreement between
momentary and recalled pain data, and, importantly for
the present study, inability to be used for telemonitoring
[19, 20]. Thus, ecological momentary assessment (EMA)
using electronic diaries has now been claimed to be the
“gold standard” in healthcare monitoring [21]. EMA,
which involves real-time, repeated assessment, has been
demonstrated to minimize recall bias and maximize
ecological validity [22]. Additionally, the use of electronic
diaries, as opposed to traditional paper diaries, enhances
compliance, reduces errors in data entry, and allows
for telemonitoring [23, 24].
An example of how assessment can be responsible for
deficits in medical treatment for pain is also given in the
context of our Pain Clinic at the Vall d’Hebron Hospital,
but may be applicable to other pain clinics worldwide.
Patients at our Pain Clinic tend to be assessed for pain
intensity, side effects of the medication, and other pain-
related variables during face-to-face appointments only.
When patients have a concern between appointments
(i.e., pain does not decrease or they are experiencing a
side effect of the medication), it is the patient’s decision
to take action. From our past experience, they either go
to emergency services, to their general practitioner,
they try to contact the Pain Clinic by phone, or they do
nothing and wait until the following appointment at the
Pain Clinic. This procedure is problematic. First, emer-
gency services and general practitioners are not special-
ized in pain treatment and have limited treatment
knowledge and options when compared to physicians at
the Pain Clinic. The phone-call procedure is inefficient,
as it is very costly (i.e., it requires that someone is avail-
able at all times at the Pain Clinic to answer to those
calls) and does not guarantee that patients’ concerns
are clinically relevant nor that all patients with clinically
relevant events call the Pain Clinic, which is a threat to
patient safety.
The use of smartphone applications in health settings
has been boosted in recent years, especially as an
alternative or adjuvant to on site, face-to-face treatments
[25–27]. However, to the best of our knowledge there is
no RCT in pain settings showing that the use of an
electronic diary for EMA increases the effectiveness of
medical treatment. The goal of the present study is to
explore whether the inclusion of a smartphone app for
daily telemonitoring of chronic pain improves the effect-
iveness of medical treatment in patients with pain. We
expect that telemonitoring will contribute to more
patient-centered care, as revealed in previous research
[17], thus resulting in reduced pain intensity ratings and
decreased duration and frequency of side effects of the
medication. To ensure that physician telemonitoring and
not the use of the app itself is responsible for increased
treatment effectiveness, a group of patients will use the
app daily without telemonitoring (no alarms in the
presence of undesired events) and compared against a
group using the app with telemonitoring. A third group
will follow the usual measurement without the app.
Methods/design
Design
This superiority, randomized controlled trial was ap-
proved by the Ethical Review Board at the Vall d’Hebron
Hospital in Barcelona (June 25, 2017) and registered in
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the clinicaltrials.gov registry on July 25, 2017 (NCT032
47725). A Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) checklist can be found
in Additional file 1.
Once eligibility is ensured, patients will be randomly
allocated to one of three conditions: (1) treatment as
usual (TAU); (2) TAU + daily assessment using the Pain
Monitor app; or (3) TAU + daily assessment using the
Pain Monitor app with alarms. Assignment will be
made by an independent researcher using an online
randomization tool. Neither patients nor physicians in
charge of treatment will be blind to allocation. The
SPIRIT flowchart is shown in Fig. 1.
Eligibility criteria
The eligibility criteria are:
a.The patient is over 18 years of age
b.The patient does not present with psychological and/
or cognitive alterations or problems with language
that make their participation difficult
c.The patient has the physical ability to use the
application
d.The patient voluntarily wants to participate and signs
the informed consent form (Additional file 2)
e.The patient has a mobile phone with an Android
operating system
Procedure
The study will be advertised by physicians working at
the pain unit of the Vall d’Hebron Hospital in Barcelona.
All consecutive patients meeting the eligibility criteria of
(a) age and (b) ability to participate will be introduced to
the study. An information sheet will be provided and if
the patient agrees to participate in the study, the inclu-
sion criteria (c) and (e) will be explored. Participants
meeting all previous inclusion criteria will be asked to
sign the informed consent form (criterion d) and will
be assigned to a previously randomized study condition.
Sample
The participants will be 150 patients with chronic pain,
attending the pain clinic at the Vall d’Hebron Hospital in
Spain. There will be no exclusion criterion in terms of
existing treatment for pain at study onset or changes in
treatment during the study, so that the sample will be
representative of patients treated at the pain clinic.
However, this information will be collected in all
participants regardless of the assigned condition.
Participants in the TAU condition will be identified
using a unique alphanumeric code. Their responses will
not contain any identifying information. The database
provided by the app (app and app+alarm condition) will
also be completely anonymized, since the system will
not store any personal information. The app will only
collect the international mobile equipment identity
(IMEI), which is a reference unique to each mobile
phone. To ensure confidentiality, the storage of partici-
pants’ IMEI will be external to the system. The file
containing the link between non-identifying codes (IMEI
or alphanumeric code) and patients’ identifying informa-
tion (medical registry number) will be stored locally in a
separate computer. Data collection and storage will
follow Spanish law and data protection rules (“Ley Orgánica
15/1999, de 13 de diciembre, de Protección de Datos
de carácter personal”, “RD 1720/2007, de 21 de diciembre,
por el que se aprueba el reglamento de desarrollo de
la LOPD (RLOPD)”, and “Ley 34/2002, de 11 de julio
de Servicios de la Sociedad de la Información y de
comercio electrónico”).
Pain monitor
Content in the app was developed by a multidisciplinary
team of psychologists, physicians, and nurses from the
Pain Clinic of the Vall d’Hebron Hospital and the Labpsitec
Fig. 1 Schedule of enrolment, interventions, and assessments. All patients received the usual treatment for their pain irrespective of their group allocation
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group of the Jaume I University via consensus after a set of
meetings. Assessed constructs were selected according to
existing guidelines on pain measurement [12, 28–30] and
included demographic information, pain characteristics
(location, duration, intensity, and neuropathic symptoms),
treatment for pain, use of rescue medication, side effects,
adherence to treatment, pain interference, fatigue, mood
(depression, anxiety, anger, and happiness), perceived
health status, pain catastrophizing, pain acceptance and
willingness, coping, fear/avoidance of pain, activity level,
and satisfaction with treatment. The assessment protocol
in the app was validated against well-established measures
in a previous study with 38 patients attending the Pain
Clinic of the Vall d’Hebron Hospital in Barcelona. These
include the Brief Pain Inventory for pain intensity and pain
interference [31], the Profile of Mood States for fatigue
and mood [32], the Hospital Anxiety and Depression Scale
for depression and anxiety [33], the Beck Depression
Inventory-II for depression [34], the Short Form 12 for
perceived health status [35], the Pain Catastrophizing Scale
for pain catastrophizing [36], the Chronic Pain Acceptance
Questionnaire for pain acceptance and willingness [37], the
Fear-Avoidance Beliefs Questionnaire for fear/avoidance of
pain [38], the Chronic Pain Coping Inventory-42 [39]
and the Coping Strategies Questionnaire [40] for
coping, and the Roland Morris Disability Questionnaire
for activity level despite pain [41]. The list of side effects
was created considering the most frequent adverse effects
of pain medication [42–44]. All the questions in the app
can be found in Additional file 3.
The primary measures will be pain intensity and side
effects of the medication, which are expected to be lower
in the app+alarm condition. Secondary measures will
include the remaining variables, including pain inter-
ference, mood, use of rescue medication, satisfaction
with treatment, perceived health status, activity level,
fear of pain, pain acceptance, and pain catastrophizing.
Again, all of these are hypothesized to show a greater
improvement in the app+alarm condition.
Two examples of app items are presented in Fig. 2.
Interventions
All participants will receive the usual medical treatment
at the pain unit, following existing guidelines for pain
management [42, 45]. During the first appointment (be-
ginning of study), physicians will propose a treatment
plan for each patient according to the aforementioned
guidelines. All patients will have a follow-up appoint-
ment 1 month after the onset of treatment (end of study).
As shown before, response to undesired clinical events
(i.e., pain is not decreasing or patient experiences side
effects of a medication) varies widely across patients and
depends on patients’ own judgment. Some patients go to
the emergency service or to the general practitioner.
Others try to contact physicians at the Pain Clinic by
phone, which is not always possible, while a subset of
patients just tolerate the symptoms and wait until the
next appointment. In all cases, the “alarm” and the
response to it is based on the patient’s criterion, which,
Fig. 2 Example of two app items
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as shown before, is problematic. In the present study,
this procedure will be representative of patients in the
TAU and TAU+app conditions. In contrast, in the TAU
+app+alarm group, clinically relevant events will be
determined by physicians in the app and alarms will be
received daily to offer a rapid response (i.e., phone
patients and make changes in the medication, which can
be collected from their general practitioner).
As indicated above, changes in pain medication may
not only occur in the alarm group, but also in the other
two conditions (i.e., if patients attend the emergency
service, their general practitioner, or if they call the Pain
Clinic), so this will be controlled at the end of the study
by looking at the hospital database.
Assessment plan
For all conditions, patients will be asked to respond to
the pre-treatment assessment during the beginning of
the study appointment, before the treatment plan is
proposed. Patients assigned to the app or app+alarm
conditions will be asked to download and complete the
pre-treatment assessment in the app. The physician will
assist in this first app use. In this pre-treatment assessment
with the app, patients have to report on demographic and
pain information. Then, participants are asked to answer
to a morning and an evening assessment daily for 30
consecutive days. Some items are asked twice a day (i.e.,
pain intensity, fatigue, and mood), while others are only
asked once, in the morning (i.e., interference of pain on
past night sleep) or in the evening (i.e., interference of pain
on leisure, activity level during the day, and side effects).
At the end of the study (day 30 of app use), information
on satisfaction with treatment and pain characteristics
(i.e., location and neuropathic symptoms) is collected. The
app uses a push system to inform patients when to
respond. Default hours are set (10 am and 7 pm), but they
can be changed with 2-h flexibility.
As usual, patients in the TAU condition will be
assessed only twice, at the beginning of the study and in
the follow-up appointment (end of study). Despite the
traditional assessment at the Pain Clinic being limited to
assessment of pain characteristics (duration, location,
intensity, and neuropathic symptoms), we will include
the whole assessment protocol used in the app to make
results comparable. As usual, this assessment will be
made in a paper-and-pencil format.
Calculations and analyses
Considering previous studies on the complications of
pain treatments [14, 46], we expect that their rapid
detection using alarms might yield moderate between-
group differences in primary measures, that is, pain
intensity and frequency and duration of side effects
(Cohen’s d = 0.5). Despite being only speculative, it is
also possible that patients allocated to the app without
alarm will perform better than those allocated to TAU, if
they also perceive that they are being telemonitored even
though they are not. However, we expect this effect to
be small. Considering 80% power, we will need 50 partic-
ipants in each group to perform the analyses. Power
calculations were made with G*Power [47]. Data will be
analyzed using the intention-to-treat principle and a
mixed-model approach [48]. Changes in secondary
measures will also be explored, although they are
expected to be small because they are not the main
target of medical intervention in the present study.
Analyses will be performed separately by the lead
researcher, C.S.R., and an independent researcher.
Interim analyses will not be performed because no harm
is expected from adding the app to the usual treatment.
The final dataset and the statistical code will be
publically accessible to all researchers under request,
excluding any personal information from the participants.
Changes to eligibility and other protocol modifications,
if any, will be discussed and communicated to relevant
parties (Ethical Review Board, clinicians, participants,
and journals).
Discussion
Treatment of pain can be complex due to individual
differences in response to interventions, the vast reper-
toire of available treatments, side effects associated with
certain interventions, and the challenges of choosing the
right dosage for a given patient [42–44, 49]. Thus, person-
alized treatments are urgently required. EMA has been
argued to be a prerequisite to achieve this improvement in
the effectiveness of treatments for chronic pain [17, 50].
There are important problems associated with the use of
paper diaries for assessment of EMA, including recall bias
and limited naturalistic value [51, 52]. The use of an app
is a promising way of dealing with limitations of paper
diaries, and is an easy tool for use in telemonitoring.
In the present study protocol, we describe a RCT
designed to test the utility of Pain Monitor, an app for
daily assessment of adults with chronic pain. The study
aims to explore whether the use of the app results in
improved pain treatment by adding a telemonitoring
tool, that is, alarms in the presence of undesired events
like side effects of the medication, lack of response to
treatment, or excessive use of rescue medication. To the
best of our knowledge this is the first study to evaluate
the impact of a smartphone app for telemonitoring in
pain settings and should reveal whether daily monitoring
indeed improves treatment effectiveness.
The present study has some limitations. Blinding
participants and healthcare professionals to allocation
was not feasible for ethical reasons. Also, the app is still
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not available for the iOS operating system, so a subset
of patients will not be able to participate in the study.
We expect this number to be small because, in Spain,
90% of smartphones use the Android operating sys-
tem [53]. If, indeed, results suggest that the use of the
app (with or without alarms) leads to improved treat-
ment, Pain Monitor will be developed for the iPhone
operating system.
Despite these limitations, if telemonitoring with Pain
Monitor leads to the hypothesized results, this will have
important clinical implications. Specifically, we expect
that daily use of Pain Monitor with alarms will lead to
more effective and safer treatments, thanks to the rapid
detection of non-response to the intervention prescribed
for pain and side effects of the medication. Additionally,
the use of Pain Monitor might also be useful to detect
changes in other pain-related variables, such as pain
interference, activity level, or psychological constructs
like pain catastrophizing or pain acceptance, which are
key elements in the multidisciplinary treatment of
chronic pain [54]. If the results support the use of Pain
Monitor, the findings will be communicated to the
relevant groups, including the Hospital Board Committee,
healthcare professionals, and patients. Also, results will be
disseminated to the wider public via scientific publication.
Trial status
The trial is currently recruiting. Recruitment started in
September 2017 and will continue until 150 participants
have been included.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 119 kb)
Additional file 2: Informed consent form. (DOCX 116 kb)
Additional file 3: Items in the Pain Monitor app. (DOCX 27 kb)
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